Biotage is Subject to Extended Patent Litigation in the US

UPPSALA, Sweden--()--Regulatory News:

Biotage AB (STO:BIOTA) has together with its subsidiaries Biotage GB Ltd and Biotage LLC (collectively “Biotage”) been sued for patent infringement of the US patents no 8,066,875 B2 and 8,070,957 in the U.S. District court for the Southern District of California. The lawsuit has been filed by Scientific Plastic Products, Inc.

These lawsuits relate to the same patent family (US patents 7,138,061, 7,381,327 and 7,410,571) that Biotage was sued for patent infringement in 2009. As previously announced, the 2009 law suit is currently subject to stayed litigation proceedings in the court while awaiting resolution from reexamination proceedings in the US Patent and Trademark Office. The US patent no 8,066,875 B2 is a continuation of the US patent no 7,381,327. This law suit, as the previous one, concerns primarily Biotage’s sale of the product line SNAP in the US. The US patent no 8,070,957 is a continuation of the US patent 7,410,571 and it is a method patent that relates to the use of FLASH chromatography products.

“Disputes concerning intellectual property rights are unfortunately becoming more and more common. It is yet too early for us to give a firm opinion on the status of this matter. Our preliminary analysis does indicate that we have a strong position and that the plaintiff does not have good cause for the alleged patent infringement. I do note that we so far have had a 100 percent success in the reexamination where we have requested USPTO to declare all claims of the US patents 7,138,061, 7,381,327 och 7,410,571 invalid.”, says Torben Jørgensen, CEO, Biotage AB.  

The information in this press release is of the kind that Biotage AB (publ) may be required to make public according to the Securities Market Act and/or Financial Instruments Trading Act. The information was released for publication at 8.00 am on January 12, 2012.

About Biotage:

Biotage offers solutions, knowledge and experience in the areas of analytical chemistry and medicinal chemistry. The customers include the world’s largest pharmaceutical and biotech companies, and leading academic institutes. The company is headquartered in Uppsala and has subsidiaries in the US, UK and Japan. Biotage has 272 employees and had sales of 428.9 MSEK in 2010. Biotage is listed on the NASDAQ OMX Nordic Stockholm stock exchange. Website: www.biotage.com

This information was brought to you by Cision http://www.cisionwire.com

Contacts

Torben Jörgensen, President and CEO
Tel: +46 707 49 05 84,
torben.jorgensen@biotage.com

Sharing

Contacts

Torben Jörgensen, President and CEO
Tel: +46 707 49 05 84,
torben.jorgensen@biotage.com